NZ779449B2 - Ready-to-use injectable formulations - Google Patents
Ready-to-use injectable formulations Download PDFInfo
- Publication number
- NZ779449B2 NZ779449B2 NZ779449A NZ77944920A NZ779449B2 NZ 779449 B2 NZ779449 B2 NZ 779449B2 NZ 779449 A NZ779449 A NZ 779449A NZ 77944920 A NZ77944920 A NZ 77944920A NZ 779449 B2 NZ779449 B2 NZ 779449B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- ready
- amount
- cefovecin
- total weight
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title claims 2
- 239000000203 mixture Substances 0.000 claims abstract 27
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims abstract 10
- 229930186147 Cephalosporin Natural products 0.000 claims abstract 5
- 241001465754 Metazoa Species 0.000 claims abstract 5
- 229960002903 benzyl benzoate Drugs 0.000 claims abstract 5
- 229940124587 cephalosporin Drugs 0.000 claims abstract 5
- 150000001780 cephalosporins Chemical class 0.000 claims abstract 5
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical group CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims abstract 4
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003125 aqueous solvent Substances 0.000 claims abstract 3
- 229960001846 cefovecin sodium Drugs 0.000 claims 7
- QRIBXVGHDLFNNE-BMCBYEKFSA-M sodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-[(2s)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1[C@@H]1CCCO1 QRIBXVGHDLFNNE-BMCBYEKFSA-M 0.000 claims 7
- 229960003391 cefovecin Drugs 0.000 claims 6
- ZJGQFXVQDVCVOK-MSUXKOGISA-N cefovecin Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1[C@@H]1CCCO1 ZJGQFXVQDVCVOK-MSUXKOGISA-N 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229940102213 injectable suspension Drugs 0.000 claims 3
- 241000282465 Canis Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention describes a ready-to-use injectable cephalosporin composition with reasonable viscosity, resuspendability, and syringeability attributes for injection as an antibiotic for animals. The composition claimed comprises a biocompatible oil that is propylene glycol dicaprylate/dicaprate in the amount of 58w/w% to 68w/w% of the total weight of the composition and a non-aqueous solvent that is benzyl benzoate in the amount of 18w/w% to 22w/w% of the total weight of the composition.
Claims (13)
1. A ready-to-use injectable suspension composition comprising a osporin which is cefovecin or cefovecin sodium, wherein the composition comprises a biocompatible oil that is propylene glycol dicaprylate/dicaprate in the amount of 58w/w% to 68w/w% of the total weight of the composition and a non-aqueous solvent that is benzyl benzoate in the amount of 18w/w% to 22w/w% of the total weight of the composition.
2. The ready-to-use composition of Claim 1, n the benzyl benzoate is in the amount of 20w/w% of the total weight of the composition and the propylene glycol dicaprylate/dicaprate is in the amount of 61w/w% to 64w/w% of the total weight of the composition.
3. The ready-to-use composition of Claim 2, wherein the cephalosporin is cefovecin sodium.
4. The ready-to-use composition of Claim 3, wherein the cefovecin of cefovecin sodium in the composition is in the amount of mL to 180mg/mL and the composition is to be administered by subcutaneous injection.
5. A ready-to-use injectable suspension composition comprising cefovecin sodium and wherein the cefovecin of cefovecin sodium in the composition is in the amount of mL to 180mg/mL; a biocompatible oil that is propylene glycol ylate/dicaprate in the amount of 60w/w% to 65w/w% of the total weight of the composition and a ueous solvent that is benzyl benzoate in the amount of 18w/w% to 22w/w% of the total weight of the composition.
6. The ready-to-use ition of Claim 5, wherein the concentration of cefovecin in the composition is 160mg/mL.
7. The ready-to-use composition of Claim 6, wherein the composition is to be administered by subcutaneous injection.
8. The ready-to-use composition of any one of Claims 1 to 6 which is for treating a bacterial infection in a companion animal.
9. The ready-to-use composition of Claim 8, wherein the companion animal is canine or feline.
10. A method of treating a bacterial ion in a companion animal in need thereof, by administering an effective amount of a cephalosporin which is cefovecin or cefovecin sodium in a ready-to-use injectable composition in any one of Claims 1 to 6.
11. The method of Claim 10, wherein the companion animal is canine or .
12. A ready-to-use injectable suspension composition comprising a cephalosporin, a biocompatible oil, and a ueous solvent, wherein the non-aqueous solvent is benzyl benzoate in the amount of about 20w/w% of the total weight of the composition, and the biocompatible oil is propylene glycol dicaprylate/dicaprate in the amount of about 61w/w% to about 64w/w% of the total weight of the ition, and the cephalosporin is cefovecin sodium wherein cefovecin of cin sodium is in an amount of about mL.
13. The ready-to-use composition of any one of Claims 1, 5 or 12, substantially as herein described with reference to any one of the examples and/or
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814440P | 2019-03-06 | 2019-03-06 | |
| PCT/US2020/021060 WO2020181024A1 (en) | 2019-03-06 | 2020-03-05 | Ready-to-use injectable formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ779449A NZ779449A (en) | 2023-11-24 |
| NZ779449B2 true NZ779449B2 (en) | 2024-02-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005237230B2 (en) | Use of meloxicam formulations in veterinary medicine | |
| ES2803648T3 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| JP2013523828A (en) | Preservative combinations for ophthalmic compositions | |
| US20150182454A1 (en) | Method of administering an injectable antibiotic to an animal | |
| RU2496501C2 (en) | Compositions containing antibiotic and corticosteroid | |
| EP3439631A1 (en) | Ophthalmic composition comprising pvp-i | |
| NZ779449B2 (en) | Ready-to-use injectable formulations | |
| NZ779449A (en) | Ready-to-use injectable formulations | |
| Nieto et al. | Pharmacokinetics of a combination of amikacin sulfate and penicillin G sodium for intravenous regional limb perfusion in adult horses | |
| Dowling | Peptide Antibiotics: Polymyxins, glycopeptides, bacitracin, and fosfomycin | |
| DK153123B (en) | METHOD FOR PREPARING A POWDER-PHARMACEUTICAL PREPARATION CONTAINING AMOXYCILLIN TRIHYDRATE | |
| Khalil et al. | Ceftiofur pharmacokinetics in Nile tilapia Oreochromis niloticus after intracardiac and intramuscular administrations | |
| US11510985B2 (en) | Oral composition for delivery of drugs and other substances | |
| EP0003618B1 (en) | Antibacterial composition and use thereof | |
| JP2019142972A5 (en) | ||
| JP2014074071A (en) | Pharmaceutical composition having relatively low ionic strength | |
| ES2752034T3 (en) | Injectable antibiotic formations and their procedures for use | |
| Skeeles et al. | Studies on the use of a long-acting oxytetracycline in turkeys: serum levels and tissue residues following injection | |
| RU2024116875A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EAR INFECTIONS | |
| EP2934524B1 (en) | Penethamate veterinary injectable formulations | |
| Lode et al. | Serum bactericidal activity and kinetics of azlocillin and moxalactam after single and combined administration | |
| AU7570891A (en) | Veterinary treatment of lambs and sheep | |
| ALBARELLOS et al. | Determination of cefquinome in synovia and plasma of horses after intramuscular administration at a dose rate of 1 mg kg) body weight |